Superpotency Risk Triggers Vitruvias Thyroid Tablets Recall 2026

A single lot of prescription thyroid medication is being pulled from pharmacies nationwide after testing revealed it could be far stronger than labeled, raising the risk of serious hormonal side effects for patients who rely on it daily. Vitruvias Therapeutics, Inc., based in Auburn, Alabama, announced on August 21, 2026 that it is voluntarily recalling one lot of Thyroid Tablets, USP 30 mg to the consumer level after confirming the product may be superpotent.

Thyroid, USP is a natural hormone preparation made from porcine thyroid glands, containing both levothyroxine and liothyronine, and is prescribed to treat hypothyroidism, or underactive thyroid. When a batch contains more active hormone than intended, patients can unknowingly be overdosed with every pill they take.

Why Was This Recall Issued?

According to the company’s announcement, testing confirmed the potential for the affected lot to be superpotent. Consuming superpotent thyroid tablets can push the body into hyperthyroidism, an overactive thyroid state that can bring on weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, a rapid heartbeat, or heart rhythm disturbances.

The company noted that certain groups face heightened danger. Elderly patients are more susceptible to cardiac complications from excess thyroid hormone, while overtreatment during pregnancy has been linked to higher rates of maternal and fetal complications, including premature delivery and low birth weight. In infants, overtreatment may interfere with normal growth and development. As of the announcement date, Vitruvias Therapeutics said it had not received any reports of adverse events tied to this recall.

Which Items Are Involved?

The recall covers a single lot of Thyroid Tablets, USP 30 mg, identified as follows:

• Product: Thyroid Tablets, USP 30 mg
• NDC: 69680-166-00
• Lot Number: 504950
• Expiration Date: 9/30/2026
• Units Released: 3,655
• Units Sold: 1,955

The lot was distributed nationwide across the United States to Vitruvias Therapeutics’ direct accounts between January 31, 2025 and September 30, 2025. Consumers are advised to check the product label against this lot information to confirm whether their supply is affected.

Who Should Be Concerned?

Because the lot was shipped nationwide to direct accounts rather than a specific region, any pharmacy or patient who received Thyroid, USP through this distribution channel during the stated window could be holding affected tablets. Patients currently taking a hypothyroidism medication should verify the NDC and lot number on their bottle rather than assuming their prescription is unaffected.

What Consumers Need to Do Now

Vitruvias Therapeutics is proactively notifying wholesalers by phone and email to halt further distribution and is arranging destruction of the recalled stock. Importantly, the company is warning patients not to simply stop taking the medication on their own.

Patients currently using Thyroid, USP from Lot 504950 should contact their healthcare provider for guidance and, if needed, a replacement prescription before discontinuing use. Stopping a thyroid medication abruptly without medical supervision carries its own health risks, so this step matters as much as identifying the affected lot.

Anyone who has experienced symptoms possibly related to this product should also contact their physician. Adverse reactions or quality issues can be reported to the FDA’s MedWatch program online, by mail, or by fax, using the agency’s standard adverse event reporting form.

What the Company Said

The recall notice states plainly that the action is being taken because testing confirmed the potential for the product to be superpotent, and that the recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Consumers with questions can reach Vitruvias Therapeutics by email at safety@vitruvias.com or by phone at (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. CT.

The FDA published the company’s announcement on its recalls, market withdrawals, and safety alerts page on August 24, 2026, three days after Vitruvias Therapeutics first issued the notice.